Business
Lexaria's Human GLP-1 Study #5 Begins Dosing
Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide Study will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April 2, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) ...
About this update from Lexaria Bioscience Corp.
[{"type":"list","items":[{"val":[{"type":"text","content":"Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"Study will investigate Pharmacokinetics and Safety","length":50,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":160,"olType":false},{"type":"text","content":"KELOWNA, BC / ACCESS Newswire / April 2, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that dosing has begun as scheduled in its human study GLP-1-H25-5 (the "Study") that is comparing oral DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide.","length":399,"tagName":"p"},{"type":"text","content":"On November 20, 2024, Lexaria reported on an earlier 12-week study in rodents which showed that with unlimited food available, oral DehydraTECH-liraglutide demonstrated a 5.88% weight reduction and an 11.54% blood sugar reduction as compared to baseline.","length":254,"tagName":"p"},{"type":"text","content":"The current Study is designed to test pharmacokinetics ("PK") (absorption into bloodstream) and adverse events in humans. Lexaria has previously shown in other GLP-1 PK studies in humans, that certain oral DehydraTECH formulations demonstrated superior bloodstream delivery, as well as reduced adverse events as compared to the oral semaglutide and injectable tirzepatide products on the market today.","length":411,"tagName":"p"},{"type":"text","content":"Liraglutide is currently sold only in an injectable form under the brand names Saxenda® and Victoza®, both manufactured by Novo Nordisk. Despite the launch of a genericized version of liraglutide by Teva Pharmaceutical Industries, Ltd. in June of 2024, Novo Nordisk generated US$1.0 billion in Saxenda® revenue, as well as an additional US$0.8 billion in Victoza® revenue during 2024.","length":384,"tagName":"p"},{"type":"text","content":"Results of the Study will be released once available.","length":53,"tagName":"p"},{"type":"text","content":"About Lexaria Bioscience Corp. & DehydraTECH","length":48,"tagName":"p"},{"type":"text","content":"DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which i...